Fulcrum Therapeutics (FULC) PT Lowered to $7 at Morgan Stanley
Tweet
Share
E-mailGet Alerts FULC Hot Sheet
Price: $3.73 +0.54%
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 7 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $7.00 (from $8.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$49 at Desjardins
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
